XSpray Pharma AB (STU:6XP) Total Debt per Share: €0.28 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6XP XSpray Pharma AB STU:6XP
28 GF Score
Price €0.79
View Full Analysis

What is XSpray Pharma AB Total Debt per Share?

XSpray Pharma AB STU:6XP -3.43% 28 Total Debt per Share is €0.28 as of Jun. 2026. GuruFocus rates STU:6XP with a GF Score™ of 28/100.

€0.28 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. XSpray Pharma AB's Total Debt Per Share for the quarter that ended in Jun. 2026 was €0.28.

XSpray Pharma AB Total Debt per Share Historical Data

* Premium members only.

The historical data trend for XSpray Pharma AB's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XSpray Pharma AB Total Debt per Share Chart

XSpray Pharma AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only 0.01 0.01 0.10 0.29 0.32

XSpray Pharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.31 0.32 0.31 0.28
STU:6XP
28GF Score
XSpray Pharma AB STU:6XP
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XSpray Pharma AB Total Debt per Share Calculation

XSpray Pharma AB's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(11.20+0.49)/42.93
=0.27

XSpray Pharma AB's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.00+11.59)/47.42
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of €0.28 mean?
XSpray Pharma AB (STU:6XP) has a Total Debt per Share of €0.28 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on XSpray Pharma AB and its competitors.
Is XSpray Pharma AB's Total Debt per Share too high?
XSpray Pharma AB's current Total Debt per Share is €0.28. Overall, XSpray Pharma AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does XSpray Pharma AB's Total Debt per Share compare to VRTX and REGN?
XSpray Pharma AB's Total Debt per Share of €0.28 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on XSpray Pharma AB and its competitors. XSpray Pharma AB's current Total Debt per Share is €0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XSpray Pharma AB stock overvalued right now?
XSpray Pharma AB (STU:6XP) has a current Total Debt per Share of €0.28. The current Total Debt per Share is €0.28. XSpray Pharma AB's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For XSpray Pharma AB (STU:6XP), the current Total Debt per Share is €0.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XSpray Pharma AB Business Description

Other Exchanges XSPRAY:Sweden0GHZ:UK
Address Scheeles vag 2, Solna, SWE, SE-171 65
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.
28GF Score

Get the complete analysis for STU:6XP

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.79
Price